back to homepage

Uncategorized

Luaskya Nonon, CEO of Equity Principle Consulting, to Speak at North Carolina Executive Roundtable’s Monthly Luncheon on The Evolution of Workplace Culture and Policies

United States – September 4, 2023 – Equity Principle Consulting is thrilled to announce that Luaskya Nonon, CEO and founder, will be the featured speaker at the upcoming North Carolina

Read More

Chemotherapy-Induced Diarrhea (CID) Market to Register Incremental Growth During the Forecast Period (2023-2032) – DelveInsight | Key Players – Napo Pharmaceuticals/Jaguar Health MYTESI (crofelemer)

Delveinsight Business Research LLP As per DelveInsight, the Chemotherapy-Induced Diarrhea Market is anticipated to evolve immensely in the coming years owing to the already prescribed products along with the launch

Read More

Hemophilia B Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Alnylam, ApcinteX, Bioverativ, CSL Behring, Genzyme, HEMA Biologics, UniQure, Sangamo

Delveinsight Business Research LLP As per DelveInsight, the Hemophilia B Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of

Read More

Acute Myeloid Leukemia (AML) Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) – DelveInsight | Gamida Cell, GlycoMimetics, ImmunityBio, Bellicum Pharmaceuticals

Delveinsight Business Research LLP As per DelveInsight, the Acute Myeloid Leukemia Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases

Read More

Pediatric Growth Hormone Deficiency Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | OPKO Health, Ascendis Pharma, Aravive

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 5+ key pharma and biotech companies are working on 5+ pipeline drugs in the Pediatric Growth Hormone Deficiency therapeutics landscape

Read More

Hemophilia B Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Amarna therapeutics, Catalyst Biosciences, Freeline

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hemophilia B pipeline constitutes key companies continuously working towards developing Hemophilia B treatment therapies, analysis of Clinical Trials, Therapies, Mechanism

Read More

Dup15q Syndrome Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Hoffmann-La Roche, Takeda

“Dup15q Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dup15q Syndrome, historical and forecasted epidemiology as well as the Dup15q Syndrome market trends in

Read More

Rare NRG1 Fusion Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Hummingbird Bioscience, Merus, Elevation Oncology

“Rare NRG1 Fusion Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Rare NRG1 Fusion, historical and forecasted epidemiology as well as the Rare NRG1 Fusion

Read More

Triple Negative Breast Cancer Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | HiberCell, Inc

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Triple Negative Breast Cancer pipeline constitutes 75+ key companies continuously working towards developing 80+ Triple Negative Breast Cancer treatment therapies,

Read More

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Pfizer, AstraZeneca, Lepu Biopharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, PD-1 Non-Small Cell Lung Cancer pipeline constitutes 30+ key companies continuously working towards developing 30+ PD-1 Non-Small Cell Lung Cancer

Read More